Better technology.  Better outcomes.™

Advanced Antimicrobial Burn, Surgical and Wound Care Dressings

New Drugs Against MRSA, Other Superbugs Still Lacking

Infectious disease experts warn that new drugs are urgently needed to treat six drug-resistant bacteria that cause most hospital infections and increasingly escape the effects of antibiotics.

The ESKAPE pathogens -- as these six bad bugs have been dubbed -- are still on the loose more than four years after the Infectious Diseases Society of America (IDSA) first drew attention to the growing shortage of effective antibiotics. As the crisis of antibiotic resistance continues to grow, the latest IDSA "Bad Bugs, No Drugs" report examines the trickle of new antibiotics in the research and development (R&D) pipeline and proposes steps to tackle the shortage.

"The six bad bugs we call the ESKAPE bacteria -- Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species -- are among the biggest threats infectious diseases physicians face today," said Helen Boucher, MD, of Tufts Medical Center in Boston, lead author of the new report, published in the Jan. 1 issue of Clinical Infectious Diseases and now available online. "We desperately need new drugs to fight them. But we also need cooperation among industry, academia, and government to create a sustainable R&D infrastructure that will fill the pipeline to meet today's needs and keep it filled with drugs that tackle tomorrow's infectious diseases threats."

When you view the Hi-Lighted List of Super Bug Infections listed on Page Two of the Full Article Above, you will see how Silverlon® eliminates these ESKAPE Pathogens in the Kirby Bauer Average Zones of Inhibition Study listed below.

Silverlon® kills Superbugs that AntiBiotics Can't

Please review the Hi-Lighted Text in the Table on Page 2 in this Study Document: Kirby Bauer Average Zones of Inhibition.

You will notice that Silverlon® has an effective Kill Rate against these Very Same Super Bug Bacteria that the Antibiotics listed in the Article above can not kill.

Silverlon® Kills Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter.

Kills MRSA fast. FDA Cleared Antimicrobial In Vitro Approved Lab

Kirby Bauer Standard Antimicrobial Susceptibility

The Kirby Bauer Standard Antimicrobial Susceptibility Test determines whether the antimicrobial agent applied to a medical device or textile is effective toward inhibiting bacterial growth. Study was performed by the FDA registered North American Science Association Inc.

Method
Antimicrobial activity of Silverlon® was evaluated by taking a broth culture of the selected organisms. The broth is inoculated onto the surface of a Mueller-Hinton agar plate in three different directions. The test sample centered on the agar surface and incubated at 25 – 37⁰C for 16 – 18 hours.

Interpretation
The Kirby Bauer Standard Antimicrobial Susceptibility Test reveals excellent antimicrobial activity of Silverlon® against four very common wound pathogens: S. aureus ATCC 33591, S. aureus ATCC 6538, P. aeruginosa ATCC 9027, E. faecalis ATCC 51575. Two of the bacterial species [Staphylococcus aureus ATCC 33591 (MRSA), and Enterococcus faecalis ATCC 51575 (VRE)] have multiple antibiotic resistance.

Antimicrobial Activity Dynamic Test ASTM E2149

The antimicrobial activity of the Silverlon® Wound Contact Dressing 4x4 was evaluated by the Antimicrobial Activity Dynamic Test of Surfaces ASTM E2149 for 10⁶ CFU/ml of Pseudomonas aeuroginosa ATCC 9027 and Staphylococcus aureus (MRSA) ATCC 33591. Study was completed by NAMSA, 3400 Cobb International Blvd., Kennesaw, GA. Lab No. 02G 0094900.

Antimicrobial Activity Dynamic Test of Surfaces ASTM E2149 The Graph above shows Silverlon®’s Rapid Kill Action against the growth of MRSA Bacteria (Staphylococcus aureus and Pseudomonas aeruginosa) per the Data from the Kirby-Bauer Antimicrobial Susceptibility Test. There is no growth of MRSA Bacteria within an hour and a half of the Silverlon® Dressing Application.

Silverlon® Topical 7 day use Antimicrobial / Antibacterial Wound Care, Burn Care, and Surgical Dressings are FDA Cleared to treat both hospital and/or community acquired MRSA wound infections. Many of Silverlon®'s hospital strength dressings are also available Over-the-Counter for general public use, and for purchase directly from this website. Available in a variety of easy to use sizes and shapes.

Silverlon® is the most effective treatment for MRSA Infected Wounds, Burns and Infected Post Surgery Incisions.

Simply put, Silverlon® Dressings offer the most effective protection for open wounds, burns, and post operative surgical incisions against MRSA Staph Bacteria. Silverlon's quick kill rate against the most common MRSA Bacteria: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli (E. Coli), Candida albicans, and Aspergillus niger

For a printer friendly version of this MRSA Infections and Silverlon® Silver Dressings Page, please click here

All of the Silverlon® Wound Care, Burn Care, and Surgical Products listed on this website are FDA Cleared. Copyright © 1998-2008 Argentum Medical, LLC. All Rights Reserved.

Silverlon® is Manufactured in the USA